Related Articles
Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate
Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: Determination of a suitable biopsy site for diagnosis
CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients
Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
Hepatic gene expression and functional changes associated with nonalcoholic steatohepatitis